30 million surgeries. No room for compromise.

Cataract is the world's leading cause of reversible blindness. With an estimated 30 million phacoemulsification procedures performed globally each year — over 10 million in India alone — even incremental improvements in surgical protocol translate into millions of better outcomes.

The shift from manual small-incision cataract surgery to premium phacoemulsification with advanced IOL platforms has been profound. Yet the difference between a good outcome and a great one is rarely the machine: it lies in the choices made before the first incision, during capsulorhexis, at OVD selection, IOL implantation, and at the close — the moment intracameral prophylaxis is or isn't given.

This protocol is written for the surgeon who already knows how to operate — and wants the evidence for every material decision they make.

The outcome starts before the incision

Premium IOL outcomes are predicated on three pre-operative pillars: a healthy ocular surface, accurate biometry, and realistic patient expectations. Failure at any pillar compounds through the surgical chain.

Ocular surface disease (OSD)

Dry eye, blepharitis, and meibomian gland dysfunction (MGD) distort the precorneal tear film, introducing topographic noise that degrades keratometric readings. A 2017 meta-analysis [1] found that untreated OSD produced clinically significant biometry errors in 23–35% of cases — errors that persist into post-operative refraction.

Protocol: Treat OSD aggressively for at least 4 weeks before biometry: lid hygiene, warm compresses for MGD, preservative-free artificial tears, and where indicated, short-course topical cyclosporine or azithromycin 1.5% for posterior blepharitis. Repeat keratometry after OSD treatment before finalising IOL power calculation.

IOL power formulae

The Barrett Universal II and Hill-RBF 3.0 formulae consistently outperform 3rd-generation formulae (SRK/T, Hoffer Q, Holladay 1) for modern short and long axial lengths. For post-LASIK eyes, the Barrett True-K or Shammas no-history formula is preferred to avoid myopic surprise from incorrect corneal power estimation.

OVD: not a filler, a surgical instrument

The ophthalmic viscoelastic device (OVD) does three distinct jobs in cataract surgery. No single OVD class excels at all three. Understanding the rheology — not just the brand — determines the right choice.

Trypan blue: the dye that saves the capsulotomy

A well-centred, circular, 5.0–5.5 mm continuous curvilinear capsulorhexis (CCC) is the most critical step in cataract surgery — it determines IOL centration, effective lens position (ELP), and long-term PCO risk. In challenging cases, trypan blue (0.06–0.1%) turns a nearly invisible anterior capsule into a vivid blue landmark.

When trypan blue is indicated

Technique

After the primary corneal incision, fill the anterior chamber with an air bubble to prevent dilution of the dye. Inject 0.1–0.2 mL of 0.06% ophthalmic-grade trypan blue under the air. Leave for 30–60 seconds, then irrigate with BSS to remove excess dye. The capsule stains a clear, controllable blue. Proceed with CCC, OVD injection, and phacoemulsification as standard.

A 2004 RCT by Bhartiya et al. [5] confirmed no significant difference in endothelial cell loss between trypan-blue-assisted and non-assisted CCC at 3-month follow-up, establishing the safety of the dye at the ophthalmic grade.

Beyond monofocal: matching the lens to the life

The IOL is the only permanent implant most patients will ever receive. The optics chosen in the operating theatre determine whether a 60-year-old will read their grandchild's messages without glasses for the next 30 years. The decision deserves rigorous patient workup and honest counselling.

The evidence for trifocal IOLs

A landmark multicentre RCT by Kohnen et al. [6] demonstrated that patients implanted with a diffractive trifocal IOL achieved spectacle independence at distance in 94.2% of cases, at intermediate in 77.8%, and at near in 70.4% — with patient satisfaction scores significantly exceeding the monofocal group despite measurable reduction in mesopic contrast. A systematic review by de Medeiros et al. [7] pooling 14 RCTs confirmed these findings and noted that neuroadaptation over 6–12 months reduced photic symptom scores by 40–60%.

One injection. Five times lower risk.

Acute post-operative endophthalmitis is the most catastrophic complication of cataract surgery — a 50% chance of permanent severe visual loss even with prompt treatment. It is also largely preventable. The evidence for intracameral antibiotic delivery at the close of surgery is now among the strongest in all of ophthalmology.

The ESCRS landmark study

The landmark ESCRS Endophthalmitis Study [8] — a multicentre RCT across 24 European centres with 16,603 patients — showed intracameral cefuroxime (1 mg in 0.1 mL) reduced post-operative endophthalmitis by 4.92-fold (p = 0.0002). This single finding shifted European guidelines from topical to intracameral prophylaxis as the standard of care. The NNT is approximately 750 — but with 10 million Indian cataract surgeries annually, that means roughly 13,000 preventable cases of endophthalmitis per year in India alone.

Why moxifloxacin has emerged as the preferred agent

Cefuroxime, while effective, is absent as a registered intracameral formulation in most markets outside Europe — and concerns about MRSA coverage and preparation from multidose vials (with dilution error risk) have driven the ophthalmic community toward commercial intracameral moxifloxacin. Advantages: broad-spectrum (Gram-positive including MRSA, Gram-negative, atypicals); commercially prepared (no dilution errors); excellent intraocular penetration; no established ciliotoxicity at standard doses.

Schultz & Dick (2016) [9] reviewing intracameral moxifloxacin series totalling 15,000+ eyes found zero cases of toxic anterior segment syndrome (TASS) at the standard 0.5 mg / 0.1 mL dose, with endophthalmitis rates consistently at 0.02–0.03% — an order of magnitude below historical unprophylaxed rates.

Endophthalmitis rates (indicative, based on published series). IC = intracameral.

The literature behind this protocol

Every recommendation in this protocol is referenced to peer-reviewed evidence. Key citations:

Agaaz Ophthalmics: every step, every product

Agaaz manufactures the complete surgical adjunct portfolio — from the first capsule stain to the closing prophylaxis injection — trusted by surgeons across 15+ countries.

All products are manufactured under ISO 13485 quality management at Agaaz Ophthalmics' Ahmedabad facility and registered for export to 15+ markets. Surgeon enquiries, institutional pricing, and sample requests through the contact page.

Surgeon quick answers